Gastrointestinal Pharmacology
Gastro-oesophageal reflux disease (GERD) occurs when gastric contents reflux into the oesophagus, causing heartburn, regurgitation, and potential complications like oesophagitis or Barrett's oesophagus. Pharmacologic therapy reduces gastric acidity, enhances oesophageal clearance, and strengthens lower oesophageal sphincter (LES) tone to alleviate symptoms and prevent complications.
🎯 Goals of Pharmacologic Treatment
Effective GERD management targets multiple pathophysiological mechanisms to control symptoms and prevent complications:
💪 Acid Suppression
- Primary Objective: Reduce gastric acid production and secretion
- Mechanism: Inhibit proton pumps or histamine receptors in parietal cells
- Clinical Benefit: Alleviates heartburn, promotes oesophageal healing
- Key Agents: PPIs (most potent), H₂ blockers (moderate effect)
- Monitoring: Symptom relief, endoscopic healing if erosive oesophagitis present
🛡️ Mucosal Protection
- Primary Objective: Create physical/chemical barrier against acid
- Mechanism: Neutralize acid or form protective layer
- Clinical Benefit: Rapid symptom relief, prevent mucosal damage
- Key Agents: Antacids, alginates, sucralfate
- Monitoring: Symptom duration, recurrence frequency
⚡ Motility Enhancement
- Primary Objective: Improve oesophageal and gastric motility
- Mechanism: Increase LES tone, accelerate gastric emptying
- Clinical Benefit: Reduce reflux frequency and volume
- Key Agents: Prokinetics (metoclopramide, domperidone)
- Monitoring: Symptom pattern, motility-related side effects
🎯 Clinical Memory Aid: Remember "AMP" for GERD treatment goals:
- Acid suppression (PPIs/H₂ blockers)
- Mucosal protection (Antacids/Alginates)
- Promote motility (Prokinetics)
⚡ Drug Classes & Mechanisms
GERD pharmacotherapy targets specific pathophysiological pathways. Understanding drug mechanisms guides rational selection based on symptom severity and complications:
🔬 Proton Pump Inhibitors (PPIs)
- Mechanism: Irreversibly inhibit H⁺/K⁺ ATPase (proton pump) in parietal cells
- Blocks final step of acid secretion
- Most potent acid suppression available
- Examples: Omeprazole, Esomeprazole, Pantoprazole, Lansoprazole, Rabeprazole
- Key Pharmacokinetics:
- Administered 30-60 minutes before meals (maximizes activation)
- Prodrugs activated in acidic parietal cell canaliculi
- Onset: 1-4 hours, Peak: 2-4 days of continuous dosing
- Duration: 24-48 hours (due to irreversible inhibition)
- Clinical Pearls:
- First-line for erosive oesophagitis and moderate-severe GERD
- Require acid-resistant enteric coating (destroyed by gastric acid)
- Interact with clopidogrel (esomeprazole, omeprazole inhibit CYP2C19)
💊 Histamine H₂ Receptor Antagonists
- Mechanism: Competitively block histamine H₂ receptors on parietal cells
- Reduce basal, nocturnal, and meal-stimulated acid secretion
- Less potent than PPIs but faster onset
- Examples: Ranitidine, Famotidine, Cimetidine, Nizatidine
- Key Pharmacokinetics:
- Onset: 1-2 hours, Duration: 6-12 hours
- Renal excretion (dose adjustment in renal impairment)
- Cross blood-brain barrier (central effects possible)
- Clinical Pearls:
- First-line for mild GERD, maintenance after PPI healing
- Excellent for nocturnal breakthrough symptoms
- Cimetidine inhibits CYP450 → multiple drug interactions
- Ranitidine withdrawn in many markets due to NDMA contamination
| Parameter | PPIs | H₂ Blockers | Clinical Implications |
|---|---|---|---|
| Potency | High (>90% acid suppression) | Moderate (50-70% suppression) | PPIs preferred for erosive disease |
| Onset of Action | Slow (days for full effect) | Rapid (1-2 hours) | H₂ blockers better for PRN use |
| Duration | Long (24-48 hours) | Short (6-12 hours) | PPIs provide sustained control |
| Tachyphylaxis | No (irreversible binding) | Yes (receptor upregulation) | H₂ blockers lose efficacy over weeks |
| Healing Rates (Oesophagitis) | 85-95% at 8 weeks | 50-60% at 8 weeks | PPIs superior for mucosal healing |
🧪 Symptom Control & Mucosal Protection
Non-prescription agents provide rapid symptom relief through acid neutralization or physical barrier formation, but lack disease-modifying effects:
⚗️ Antacids
- Mechanism: Chemical neutralization of gastric HCl
- Raise gastric pH rapidly (within minutes)
- Inactivate pepsin at pH >4
- Examples:
- Magnesium hydroxide (Milk of Magnesia) - causes diarrhea
- Aluminium hydroxide - causes constipation
- Calcium carbonate (Tums) - potential acid rebound
- Sodium bicarbonate - rapid but short-acting
- Clinical Use: PRN for mild, intermittent symptoms
- Take 1 hour after meals and at bedtime
- Avoid within 2 hours of other medications (binds drugs)
- Key Limitation: No mucosal healing; symptom control only
🛡️ Alginates (Raft-Forming Agents)
- Mechanism: Form viscous gel "raft" that floats on gastric contents
- Physical barrier preventing reflux
- Often combined with antacids (Gaviscon)
- Examples: Sodium alginate, potassium bicarbonate combinations
- Clinical Use: Postprandial reflux, pregnancy GERD
- Take after meals (when reflux most likely)
- Safe in pregnancy (Category B)
- Advantage: Physical action (no systemic effects)
🩹 Mucosal Protectants
- Mechanism: Form protective barrier over damaged mucosa
- Sucralfate: polymerizes in acid, binds proteins
- Bismuth compounds: antimicrobial + protective effects
- Examples: Sucralfate, Bismuth subsalicylate
- Clinical Use: Adjunctive therapy, radiation oesophagitis
- Take on empty stomach (1 hour before meals)
- Avoid with other medications (binds in GI tract)
- Key Point: Minimal systemic absorption, local action only
🔥 HIGH-YIELD: Antacid Formulation Trade-offs
- Magnesium-based: Fast-acting but causes diarrhea; avoid in renal failure
- Aluminium-based: Causes constipation; risk of accumulation in renal failure
- Calcium-based: Potential acid rebound; risk of hypercalcemia with overuse
- Sodium-based: Rapid but short duration; avoid in hypertension/heart failure
- Combination products: Balance effects (e.g., Maalox = Al + Mg)
⚙️ Prokinetic Agents & Adjuncts
Prokinetics enhance GI motility but have significant side effect profiles. They're reserved for specific GERD subtypes with motility dysfunction:
🚀 Prokinetic Agents
- Metoclopramide:
- Mechanism: Dopamine D₂ antagonist + 5-HT₄ agonist Increases acetylcholine release → enhances LES tone and gastric emptying
- Dosing: 5-10mg before meals and at bedtime Maximum 40mg/day; short-term use only (≤12 weeks)
- Adverse Effects:
- Extrapyramidal symptoms (dystonia, parkinsonism, tardive dyskinesia)
- Hyperprolactinemia (galactorrhea, gynecomastia)
- Contraindicated in Parkinson's disease, pheochromocytoma
- Clinical Use: GERD with documented gastroparesis
- Domperidone:
- Mechanism: Peripheral dopamine antagonist (poor CNS penetration) Fewer CNS effects than metoclopramide
- Dosing: 10-20mg before meals Available in limited markets due to cardiac risks
- Adverse Effects:
- QT prolongation, ventricular arrhythmias
- Hyperprolactinemia (less CNS effects than metoclopramide)
- Contraindicated with CYP3A4 inhibitors, congenital long QT
- Clinical Use: Alternative when metoclopramide contraindicated
🔄 Emerging & Adjunctive Therapies
- Baclofen: GABA-B agonist → reduces transient LES relaxations Off-label use for refractory GERD; significant CNS side effects limit use
- Lesogaberan: GABA-B agonist with better side effect profile Investigational; targets underlying reflux mechanism
- Potassium-competitive acid blockers (P-CABs):
- Vonoprazan, revaprazan - reversible proton pump inhibition
- Faster onset than PPIs, no need for acid activation
- Available in some Asian markets; emerging alternative to PPIs
- Key Principle: Prokinetics address motility component but DO NOT replace acid suppression for mucosal healing
🔍 PROKINETIC PRECAUTIONS:
- Metoclopramide: Black box warning for tardive dyskinesia (risk increases with duration and dose)
- Domperidone: Restricted in US/Europe due to cardiac risks; requires ECG monitoring
- General Rule: Use lowest effective dose for shortest duration; avoid in elderly
- Monitoring: Regular assessment for movement disorders, cardiac symptoms
📊 Comprehensive Drug Comparison
| Drug Class | Representative Agents | Mechanism of Action | Onset/Duration | Key Adverse Effects | Clinical Applications |
|---|---|---|---|---|---|
| PPIs | Omeprazole, Esomeprazole, Pantoprazole | Irreversible H⁺/K⁺ ATPase inhibition | Onset: 1-4h Duration: 24-48h |
Headache, diarrhea, C. diff risk, hypomagnesemia, B₁₂ deficiency | Erosive oesophagitis, moderate-severe GERD, maintenance therapy |
| H₂ Blockers | Famotidine, Nizatidine, Cimetidine | Competitive H₂ receptor blockade | Onset: 1-2h Duration: 6-12h |
Headache, confusion (elderly), CYP inhibition (cimetidine) | Mild GERD, nocturnal symptoms, step-down therapy |
| Antacids | Al(OH)₃, Mg(OH)₂, CaCO₃ | Chemical acid neutralization | Onset: 5-10min Duration: 1-2h |
Diarrhea (Mg), constipation (Al), acid rebound (Ca), electrolyte disturbances | PRN mild symptoms, adjunct to other therapy |
| Alginates | Sodium alginate + bicarbonate | Physical barrier formation | Onset: 5-10min Duration: 2-4h |
Minimal (bloating, nausea) | Postprandial reflux, pregnancy GERD |
| Prokinetics | Metoclopramide, Domperidone | Dopamine antagonism → ↑ motility | Onset: 30-60min Duration: 4-6h |
EPS, hyperprolactinemia, cardiac effects (domperidone) | GERD with gastroparesis, refractory cases |
⚠️ Adverse Effects & Monitoring
🔴 PPI-Specific Concerns
- Nutritional Deficiencies:
- Hypomagnesemia: Monitor Mg²⁺ yearly with chronic use; presents with muscle cramps, arrhythmias
- Vitamin B₁₂ deficiency: Reduced absorption due to decreased acid; monitor annually in elderly
- Iron/calcium malabsorption: Acid needed for solubilization; consider supplements
- Infectious Risks:
- C. difficile diarrhea: 1.7-2.5x increased risk; higher with hospital/antibiotic use
- Community-acquired pneumonia: 30-50% increased risk (especially first weeks)
- Small intestinal bacterial overgrowth (SIBO): Due to reduced gastric acidity
- Other Concerns:
- Acute interstitial nephritis: Rare but serious; monitor creatinine
- Osteoporosis fractures: Controversial; may reduce calcium absorption
- Rebound acid hypersecretion: Upon discontinuation; taper gradually
🔄 Management Strategies
- Step-Down Therapy: After 8 weeks of PPI for erosive oesophagitis, step down to H₂ blocker or lowest PPI dose
- On-Demand vs Continuous:
- Continuous: Erosive disease, Barrett's oesophagus, severe symptoms
- On-demand: Non-erosive GERD, mild-intermittent symptoms
- Intermittent: 2-4 week courses for symptom flares
- Monitoring Schedule:
- Baseline: CBC, electrolytes, renal function
- Annual: Magnesium, B₁₂ (chronic users), symptom reassessment
- As needed: Endoscopy for alarm symptoms (dysphagia, weight loss, bleeding)
🚨 GERD PHARMACOTHERAPY RED FLAGS
⚡ ADVERSE EVENT RECOGNITION
- Metoclopramide toxicity: Acute dystonic reactions (opisthotonus, oculogyric crisis) → diphenhydramine/benztropine
- PPI-induced hypomagnesemia: Muscle cramps, tetany, arrhythmias → check Mg²⁺, replete, consider discontinuation
- C. difficile colitis: Watery diarrhea, abdominal pain, fever → stop PPI, test for toxin, treat with antibiotics
- Domperidone cardiotoxicity: Palpitations, syncope, QT prolongation → ECG, discontinue drug
⚕️ TREATMENT FAILURE RESPONSE
- Inadequate response to PPI: Consider compliance, dosing timing, nocturnal breakthrough (add H₂ blocker)
- Rapid symptom recurrence: Evaluate for rebound hypersecretion, alternative diagnoses (e.g., eosinophilic oesophagitis)
- Alarm symptoms: Dysphagia, odynophagia, weight loss, anemia → urgent endoscopy
- Refractory GERD: Re-evaluate diagnosis, consider pH monitoring, surgical referral
🎯 Clinical Pearls & Prescribing Principles
- Stepwise Approach: Start with lifestyle modifications → antacids/alginates PRN → H₂ blockers → PPIs based on severity
- PPI Administration: 30-60 minutes before breakfast (once daily) or before breakfast and dinner (twice daily)
- H₂ Blocker Timing: Bedtime dosing optimal for nocturnal symptoms; can combine with morning PPI
- Therapeutic Trial: 8-week PPI trial diagnostic for GERD; response supports diagnosis
- Long-term Management: Use lowest effective dose; attempt dose reduction or discontinuation yearly
- Special Populations:
- Pregnancy: Alginates/antacids first-line; ranitidine (previously), omeprazole if needed
- Elderly: Avoid metoclopramide (CNS effects); monitor for drug interactions
- Renal impairment: Adjust H₂ blocker dose; avoid magnesium-containing antacids
- Drug Interactions: PPIs reduce absorption of ketoconazole, itraconazole, iron; increase clopidogrel effect variability
🔬 HIGH-YIELD EXAM POINTS:
- PPI superiority: Heals erosive oesophagitis better than H₂ blockers
- Tachyphylaxis: Occurs with H₂ blockers (weeks), not PPIs
- Nocturnal breakthrough: Add bedtime H₂ blocker to daytime PPI
- Metoclopramide black box: Tardive dyskinesia risk limits long-term use
- Rebound acid secretion: Occurs after stopping PPIs; taper over 4-8 weeks
- Barrett's oesophagus: Requires indefinite PPI therapy to reduce cancer risk
🧭 Conclusion
GERD pharmacotherapy employs a strategic approach targeting acid suppression, mucosal protection, and motility enhancement. Proton pump inhibitors represent the cornerstone of treatment for moderate to severe disease, offering superior acid control and mucosal healing compared to other agents.
Therapeutic decisions must balance efficacy with safety considerations, particularly for long-term management. PPIs, while highly effective, carry risks of nutritional deficiencies, infections, and rebound phenomena that necessitate judicious prescribing and regular monitoring.
H₂ receptor antagonists maintain a role in mild disease and nocturnal symptom control, while antacids and alginates provide rapid relief for intermittent symptoms. Prokinetic agents, limited by their adverse effect profiles, are reserved for specific cases with documented motility dysfunction.
Optimal GERD management integrates pharmacotherapy with lifestyle modifications, employs the lowest effective dose for the shortest necessary duration, and remains vigilant for alarm symptoms that warrant endoscopic evaluation. Through this balanced approach, clinicians can effectively control symptoms, promote healing, and prevent complications while minimizing treatment-related risks.
GERD pharmacotherapy strategically suppresses acid while protecting mucosa — understanding drug mechanisms and limitations enables targeted treatment that balances efficacy with safety across the spectrum of reflux disease severity.